18 completed, 6 terminated, 6 unknown, 1 withdrawn. 19 Phase 2, 10 Phase 3, 7 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 12, Unknown 4, Terminated 3 |
| Phase 3 | 10 | Completed 4, Unknown 3, Terminated 2, Withdrawn 1 |
| Phase 1 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow epratuzumab: new trials by email Literature Review of epratuzumab trials Research Report on epratuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 SR-A + Epratuzumab, SR-B + Epratuzumab - Acute Lymphoblastic Leukemia (ALL) | Phase 3 | Completed | Charite University, Berlin, Germany | 700 | 2014-05-01 | 2024-02-09 |
| Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Epratuzumab - Systemic Lupus Erythematosus | Phase 2 | Completed | UCB Pharma | 17 | 2012-01-01 | 2016-05-06 |
| Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Placebo, Epratuzumab 400 mg, Epratuzumab 1200 mg - Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Completed | UCB Pharma | 20 | 2011-10-01 | 2014-02-12 |
| Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Epratuzumab - Systemic Lupus Erythematosus | Phase 3 | Completed | UCB Pharma | 1250 | 2011-07-01 | 2018-10-03 |
| Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Placebo, Epratuzumab - Systemic Lupus Erythematosus | Phase 3 | Completed | UCB Pharma | 791 | 2010-12-01 | 2020-12-04 |
| Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Epratuzumab, Placebo - Systemic Lupus Erythematosus | Phase 3 | Completed | UCB Pharma | 793 | 2010-12-01 | 2018-09-28 |
| Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+ Epratuzumab and 90Y-Epratuzumab - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Nantes University Hospital | 21 | 2010-11-01 | 2014-06-25 |
| Multi-centric Study Epratuzumab - B ALL, CD22+ Expression | Phase 2 | Completed | Nantes University Hospital | 57 | 2010-11-01 | 2026-09-14 |
| S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia epratuzumab, clofarabine, cytarabine - Leukemia | Phase 2 | Completed | SWOG Cancer Research Network | 35 | 2010-09-01 | 2017-11-06 |
| Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) humanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab - Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | Phase 1 / Phase 2 | Unknown | Queen Mary University of London | 55 | 2010-01-01 | 2014-07-14 |
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) Epratuzumab, Fludarabine, Cyclophosphamide - Leukemia, Pediatric Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2009-07-01 | 2014-05-22 |
| Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Epratuzumab - Systemic Lupus Erythematosus | Phase 2 | Completed | UCB Pharma | 210 | 2008-05-01 | 2012-07-12 |
| Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma epratuzumab, rituximab - Lymphoma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 60 | 2008-03-01 | 2016-07-06 |
| Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Epratuzumab, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | UCB Pharma | 227 | 2008-01-01 | 2011-09-12 |
| Study of Epratuzumab in Systemic Lupus Erythematosus Epratuzumab - Systemic Lupus Erythematosus | Phase 3 | Withdrawn | UCB Pharma | 2007-01-01 | 2014-05-21 | |
| Study of Epratuzumab in Systemic Lupus Erythematosus Epratuzumab - Systemic Lupus Erythematosus | Phase 2 | Completed | UCB Pharma | 29 | 2006-06-01 | 2012-07-12 |
| Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma epratuzumab, rituximab, cyclophosphamide - Lymphoma | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 107 | 2006-01-01 | 2019-10-09 |
| Study of Epratuzumab in Systemic Lupus Erythematosus epratuzumab - Systemic Lupus Erythematosus | Phase 3 | Terminated | UCB Pharma | 510 | 2005-06-01 | 2011-11-08 |
| Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Epratuzumab, Placebo - Systemic Lupus Erythematosus | Phase 3 | Terminated | UCB Pharma | 54 | 2005-05-01 | 2012-06-07 |
| Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) epratuzumab - Lupus Erythematosus, Systemic | Phase 2 | Terminated | UCB Pharma | 20 | 2005-04-01 | 2012-04-03 |
Showing 20 of 31. Sign in to see all of them.
Lupus Erythematosus, Systemic (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Burkitt Lymphoma (3) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Hematologic Diseases (1) · Hemostatic Disorders (1) · Lymphoproliferative Disorders (1)
UCB Pharma (12) · Gilead Sciences (5) · Alliance for Clinical Trials in Oncology (2) · Jonsson Comprehensive Cancer Center (2) · Nantes University Hospital (2) · Amgen (1) · Charite University, Berlin, Germany (1) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Queen Mary University of London (1) · SWOG Cancer Research Network (1) · Stanford University (1)
United States (23) · United Kingdom (10) · France (9) · Belgium (8) · Italy (8) · Spain (8) · Brazil (7) · Germany (7) · Hungary (6) · Canada (5) · Czechia (5) · Poland (5) · Australia (4) · India (4) · Lithuania (4)
Anna Barry (4) · William A. Wegener, MD, PhD (2) · Anjali Advani, MD (1) · Anna Franklin, MD (1) · Arend von Stackelberg, MD (1) · Barbara Grant, MD (1) · Chevallier Patrice, MD (1) · Christos E. Emmanouilides, MD (1) · Elizabeth Raetz, MD (1) · Ivana Micallef, MD (1) · Matthew Smith, Doctor (1)
PMID 33687069, PMID 27598855, PMID 29381843, PMID 21383282, PMID 21673350, PMID 23313811, PMID 23922187, PMID 25552705, PMID 26316325, PMID 26382733, PMID 26687796, PMID 27282998, PMID 29618479, PMID 30575311, PMID 35787017, PMID 37341952
U10CA031946 (1), U10CA032102 (1), U10CA098543 (1)